Research
Hormonal
Pharmacological interventions with GLP-1 receptor agonists (e.g., semaglutide 2.4 mg, tirzepatide) and SGLT2 inhibitors promote weight loss and improve glycemic control, contributing to diabetes remission and reduced cardiovascular/renal risks.
If lifestyle changes alone aren't enough to control your diabetes or help you lose weight, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are weekly injections that help you lose weight and can put type 2 diabetes into remission for many people. They also protect your heart and kidneys. They are not just 'diet pills' but powerful tools for managing the disease.
GoodSupportsHIGH confidence
Almost half of the patients who received semaglutide 2.4 mg achieved a loss of > 10% body weight, and > 60% patients attained remission of T2DM at 68 weeks... Tirzepatide... demonstrated remarkable outcomes in individuals with obesity and T2DM.
Why this rating
Supported by multiple large RCTs (STEP 2, SURPASS trials).
Source
Treat Obesity to Treat Type 2 Diabetes Mellitus
Cem Sulu et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01536-3
narrative_reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sustained weight loss of 15 kg or more through structured lifestyle interventions (such as total meal replacement diets) can induce remission of type 2 diabetes in early-stage patients.Good
- Obesity is a root cause of type 2 diabetes, and weight loss reduces the risk of microvascular complications (retinopathy, nephropathy) and improves renal function.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →